Published on : May 15, 2017
Albany, New York, May 15, 2017: Since many years, Cancer treatment market is growing at a significant rate due to increase in the incidence of cancer cases, growing awareness among people about various stages and availability of treatment of cancer. By looking at these factors, a new study focusing on the therapeutics market of breast cancer has been analyzed and added to the broad database of Market Research Hub (MRH), with a title of “Breast Cancer Therapeutics in Southeast Asia Markets to 2022 - Increasing Prevalence and Usage of Premium Targeted Therapies to Drive the Market”. The research study highlights overall therapeutic development market along with its pipeline analysis, clinical trial analysis, marketed products, deal and strategic consolidations.
According to the research key findings, aging population and change in lifestyle habits, Increasing awareness and diagnosis of cancer; the potential launch of biosimilars to increase treatment pool; launch and uptake of pipeline products and continued uptake of existing premium-priced therapies are boosting the Southeast Asia market. Moreover, the study provides a multi-scenario forecast on Southeast Asian markets with a major focus on Singapore, South Korea, Malaysia, Taiwan, Thailand, Philippines, Indonesia and Vietnam. In the initial section, the report starts by presenting the disease introduction, its symptoms, etiology, diagnosis and treatment options.
Breast cancer, a malicious neoplasm, is the second most common cancer and the most common cancer in women worldwide, accounting for 16% of all female cancers, making the disease exceedingly prevalent. Breast cancer refers to the uncontrolled growth of malignant cells in the breast tissue. Most breast cancers are invasive cancers that have grown beyond the ducts or lobules. The first symptoms of breast cancer are usually an area of thickened tissue in the woman's breast. Women are usually diagnosed with breast cancer after a repetitive breast cancer screening, or after detecting definite signs and symptoms. Patients can be segmented into two types:
- Human epidermal growth factor receptor (HER) 2-negative segment
- HER2-positive segment
Survival for HER2-positive breast cancer patients has increased, due to established disease management strategies using numerous combinations of chemotherapy along with targeted therapies such as Herceptin, Tykerb (lapatinib) and Perjeta (pertuzumab). The report further describes that treatment of breast cancer depends on various factors such as the type of breast cancer, size of the tumor, stage of breast cancer and the grade of cancer cells. Some of the methods that are commonly used for the treatment of breast cancer are surgery, radiation therapy, chemotherapy, hormone therapy, targeted therapy and bone-directed therapy. Chemotherapy is the mainstay of treatment in this setting.
At present, the Southeast Asia breast cancer market contains well-established novel targeted products such as Perjeta and Kadcyla, tyrosine kinase inhibitors such as Tykerb, and CDK inhibitors such as Ibrance. Also, In South Korea, Singapore and Taiwan the continued uptake of targeted therapies and other premium branded drugs will contribute to the ACoT. The premium therapies Kadcyla and Perjeta are due to be approved in Indonesia, Thailand, Vietnam and Malaysia during the forecast period.
Click here to get more info with TOC in a PDF Format : https://www.marketresearchhub.com/enquiry.php?type=S&repid=1068037
About Market Research Hub
Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.
For Enquiries, Call :
+1-800-998-4852US Toll Free
Email : email@example.com